These findings collectively indicate that modulation of the gut microbiota–SCFA–GPR axis plays a pivotal role in alleviating DN-associated renal fibrosis, supporting its potential as a microbiota-targeted therapeutic strategy for improving renal outcomes in DN. This evidence concerns the gene ALDH18A1 and liver dysplastic nodule.